Last reviewed · How we verify
Betaprone (PROPIOLACTONE)
At a glance
| Generic name | PROPIOLACTONE |
|---|---|
| Sponsor | Allergan/AbbVie |
| Drug class | propiolactone |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Antiseptic preparation
Common side effects
- Pain (injection-site)
- Tenderness (injection-site)
- Swelling (injection-site)
- Redness (injection-site)
- Irritability
- Myalgia
- Malaise
- Headache
- Diarrhea
- Loss of appetite
- Fatigue
- Itching (injection-site)
Key clinical trials
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects (PHASE1)
- Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study) (PHASE4)
- Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intradermally (PHASE4)
- A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betaprone CI brief — competitive landscape report
- Betaprone updates RSS · CI watch RSS
- Allergan/AbbVie portfolio CI